Highlights

• Melrose kept its full-year guidance unchanged after group Revenue rose 4% across the July to October period.

• Engines revenue increased 3% and Airframes revenue grew 5%, while year-to-date group revenue was 8% higher.

• The aerospace group secured about £2.4bn of new three-year facilities, adding roughly £0.2bn of funding headroom.

• Melrose confirmed that its Garden Grove Facility in California has received regulatory approval to restart operations.

Steady guidance, a refinancing and a restart approval: those three threads run through the latest trading update from aerospace group Melrose (LSE:MRO). Published at 7am under the headline "guidance for full year unchanged", the statement covers trading from July to October and sets out the company's financial framework for the remainder of 2026.

Melrose revenue growth across Engines and Airframes

Group revenue increased 4% in the July to October period, according to the update. Within that, the Engines division grew 3% and Airframes grew 5%. On a year-to-date basis, group revenue was 8% higher. Adjusted operating profit for the period was in line with the company's expectations.

Melrose (LSE:MRO) is the owner of GKN Aerospace, and its two divisions, Engines and Airframes, are the lenses through which the company reports its trading performance.

Full-year guidance held steady

The company kept its guidance unchanged on a basis that excludes the Garden Grove facility. That guidance is for revenue of £3,750m to £3,950m, adjusted operating profit of £700m to £750m and free Cash Flow of £150m to £200m.

Leaving these ranges in place with two months of the year to go gives shareholders in LSE stocks a fixed reference point ahead of the full-year results. The free cash flow range is particularly closely followed, as it shows how much of the year's operating profit the company expects to convert into cash after investment, and the update leaves that expectation where it was.

Garden Grove restart and its expected financial effect

Melrose (LSE:MRO) said its Garden Grove site in California has received regulatory approval to restart. The company expects the facility to reduce FY 2026 revenue by £50m to £55m and adjusted operating profit by £40m to £45m, separate from the guidance ranges above. It put the total full-year cash effect at £70m to £80m.

Setting these figures out separately lets investors see the underlying guidance and the site-specific effect side by side. The restart itself is the operational milestone the update highlights, and it marks a step towards the site returning to its normal role within the group's production footprint.

Refinancing strengthens the funding position

Melrose also secured about £2.4bn of three-year facilities. According to the update, the refinancing adds about £0.2bn of headroom. Committed bank facilities give a company access to funding over a defined period, and a longer Maturity profile can support planning for Investment and working capital. Completing the refinancing alongside a trading update means shareholders receive the operating figures and the funding arrangements in a single statement.

The considerations identified by the company itself are the Garden Grove effects quantified above; these are reported separately from the core guidance.

Next steps for the aerospace group

Investors are likely to track how the Garden Grove restart progresses, whether revenue and profit land within the unchanged ranges, and how free cash flow develops by the year end. The full-year results will provide the complete figures for 2026, and the UK stock market will also look for any first view of 2027 from the GKN Aerospace owner.

Two divisions, one aerospace group

Melrose describes its trading through two divisions, Engines and Airframes, both part of GKN Aerospace. In the July to October period Engines revenue increased 3% and Airframes 5%, giving group growth of 4%, while year-to-date group revenue was 8% higher. Adjusted operating profit for the period was in line with the company's expectations. Reporting by division lets shareholders see how each part of the Business contributes, and it makes the update easier to compare with earlier statements. The unchanged guidance ranges of £3,750m to £3,950m for revenue and £700m to £750m for adjusted operating profit then provide the full-year frame.

Free cash flow and the Garden Grove effect

The free cash flow range of £150m to £200m is one of the most closely followed items because it shows how much operating profit is expected to turn into cash after investment. Melrose has kept it unchanged, excluding Garden Grove. For the California site, which has received regulatory approval to restart, the company expects a reduction of £50m to £55m in FY 2026 revenue, £40m to £45m in adjusted operating profit and a total full-year cash effect of £70m to £80m. Reporting those figures separately lets readers see the underlying guidance and the site-specific effect side by side.